Cannabis and spasticity
Browse the latest research linking medical marijuana / medicinal cannabis and spasticity.
Cannabis is an accepted medical use for the treatment of spasticity.
Click on a study title below to open a new tab with full article, or click on a compound to see it's full list of research.
Compounds Topics Title Date
cannabis ms,spasticity in humans via survey (n=29) Cannabis Use in People with Multiple Sclerosis and Self-Reported Spasticity Apr 2019
Positive  All subjects reported cannabis being somewhat or very helpful for pain and 78% (7/9) reported similar benefit for spasticity.
cannabis ms,spasticity,pain in humans via placebo trial (n=30/37) Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial Jul 2012
Ingestion Method: inhaled 0.8g cigarette, 4% THC
Positive  Using an objective measure, we saw a beneficial effect of inhaled cannabis on spasticity among patients receiving insufficient relief from traditional treatments. Although generally well-tolerated, smoking cannabis had acute cognitive effects.
cannabis ms,spasticity in humans via placebo trial (n=37/50) Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Aug 2004
Ingestion Method: oral 2.5mg THC/0.9mg CBD
Positive  A standardized Cannabis sativa plant extract might lower spasm frequency and increase mobility with tolerable side effects in MS patients with persistent spasticity not responding to other drugs.
cannabinoids pain,spasticity,hiv,sedative in humans via review Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. Jun 2015
Positive  Most trials showed improvement in symptoms associated with cannabinoids but these associations did not reach statistical significance in all trials. Compared with placebo, cannabinoids were associated with a greater average number of patients showing a complete nausea and vomiting response (47% vs 20%; odds ratio [OR], 3.82 [95% CI, 1.55-9.42]; 3 trials), reduction in pain (37% vs 31%; OR, 1.41 [95% CI, 0.99-2.00]; 8 trials), a greater average reduction in numerical rating scale pain assessment